There has been confusion and misunderstandings about vaccines. But vaccinations are an important part of family and public health. Vaccines prevent the spread of contagious, dangerous, and deadly diseases.
The world's famous medical journal 'Lancet' has been stamped on the effectiveness and safety of this indigenous vaccine made in India, Covaxin. The medical journal stated that phase three data of the vaccine demonstrated a 77.8 percent efficacy against symptomatic COVID-19 and also a 70.8 percent protection against all variants of SARS-CoV-2 virus.
The main findings from the journal state that:
• Covaxin shows a 77.8 percent efficacy against symptomatic COVID-19 and
a 63.6 percent protection against asymptomatic COVID-19
• The analysis demonstrates Covaxin to be 93.4 percent effective
against severe symptomatic COVID-19
• Covaxin demonstrates a 65.2 percent efficacy against the easily
transmissible Delta variant of coronavirus
• Efficacy data demonstrates 70.8 percent protection against all variants of SARS-CoV-2 virus
Dr. Krishna Ella, CMD of Bharat Biotech said, “The peer-review of Covaxin phase III clinical trial data in The Lancet, an authoritative voice in global medicine, validates our commitment to data transparency and meeting the stringent peer-review standards of world-leading medical journals. This accomplishment reflects the undeterred commitment by my team members at Bharat Biotech, our public partners, Indian Council of Medical Research, National Institute of Virology, and the trust imposed by our trial participants who made this happen.”
Also read: Two Zika virus cases found in UP's Lucknow
Dr. Balram Bhargava, Director General, Indian Council of Medical Research (ICMR) said, "I am delighted to see that the phase III efficacy data has also been published in The Lancet, one of the most reputed journals worldwide. This itself speaks highly about the strong position of Covaxin amongst other global front-runners Covid-19 vaccines. The bench to bedside journey of Covaxin in less than 10 months showcases the immense strength of “Atmanirbhar Bharat” along with the Indian academia and industry in fighting against the odds and carving a niche in the global community.”